Theravance Biopharma Acquired by Zymeworks for $17 per Share
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 50 minutes ago
0mins
Source: PRnewswire
- Acquisition Agreement: Theravance Biopharma has entered into a definitive agreement with Zymeworks to be acquired for $17 per share in cash, representing an equity value of approximately $929 million, reflecting market recognition of Theravance's assets.
- Shareholder Benefit Assurance: In addition to cash, Theravance shareholders will receive a contingent value right entitling them to 80% of net proceeds from any future licensing or monetization of ampreloxetine over the next ten years, ensuring their interests in potential future gains.
- Strategic Review Outcome: This transaction is the result of a comprehensive evaluation by Theravance's Strategic Review Committee aimed at maximizing shareholder value, which previously included monetizing the TRELEGY® royalty for $225 million.
- Future Outlook: The transaction is expected to close in the second half of 2026, subject to shareholder and regulatory approvals, providing immediate cash flow to Theravance shareholders while preserving opportunities for future potential earnings.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TBPH?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TBPH
Wall Street analysts forecast TBPH stock price to rise
5 Analyst Rating
4 Buy
1 Hold
0 Sell
Strong Buy
Current: 17.390
Low
13.00
Averages
28.40
High
42.00
Current: 17.390
Low
13.00
Averages
28.40
High
42.00
About TBPH
Theravance Biopharma, Inc. is a biopharmaceutical company primarily focused on the development and commercialization of medicines for the specialty respiratory and neurologic diseases. The Company operates through a single segment, namely, development and commercialization of human therapeutics. Its product, YUPELRI (revefenacin) inhalation solution, is a nebulized long-acting muscarinic antagonist used for the treatment of patients with chronic obstructive pulmonary disease (COPD). COPD is a long-term lung disease that includes chronic bronchitis, emphysema, or both. YUPELRI is an anticholinergic medicine, which helps the muscles around the airway in the lungs stay relaxed to prevent symptoms, such as wheezing, shortness of breath, and others. Its Ampreloxetine, is a late-stage investigational norepinephrine reuptake inhibitor in development for the treatment of symptomatic neurogenic orthostatic hypotension in patients with Multiple System Atrophy.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Theravance Biopharma to be Acquired by Zymeworks for $17.00 per Share
- Acquisition Details: Theravance Biopharma has entered into a definitive agreement with Zymeworks to be acquired for $17.00 per share in cash, representing an equity value of approximately $929 million, highlighting recognition of the company's assets and future potential.
- Shareholder Benefit Assurance: In addition to cash, Theravance shareholders will receive a contingent value right entitling them to 80% of net proceeds from any future monetization of ampreloxetine over the next ten years, enhancing the investment appeal by providing additional revenue opportunities.
- Strategic Review Process: This transaction follows a comprehensive evaluation by the company's Strategic Review Committee and Board of Directors, demonstrating the company's commitment to maximizing shareholder value, which previously included the successful monetization of a $225 million royalty interest in TRELEGY®.
- Future Outlook: The transaction is expected to close in the second half of 2026, subject to shareholder approval and customary closing conditions, and upon completion, it will provide immediate cash flow to Theravance shareholders while preserving future potential earnings from ampreloxetine.
See More
Zymeworks Acquires Theravance Biopharma for $929M
- Acquisition Overview: Zymeworks announced its acquisition of Theravance Biopharma in an all-cash deal valued at approximately $929 million, paying $17 per share, aimed at expanding its commercial portfolio with the COPD treatment YUPELRI.
- Financial Impact Analysis: YUPELRI currently generates about $60 million in annual cash flow, and the acquisition includes additional royalty interests, milestone payments, and approximately $2.5 billion in Irish tax attributes, which are expected to significantly enhance Zymeworks' financial position.
- Financing Structure: The deal will be financed primarily through a $350 million non-recourse note from OMERS Life Sciences, Theravance's expected $360 million net cash balance at closing, and $219 million of Zymeworks' cash, showcasing a diverse financing strategy.
- Approval and Expectations: The boards of both companies have unanimously approved the transaction, which is expected to close in the second half of 2026; however, TBPH stock dropped 3% in pre-market trading on Monday, indicating some market skepticism despite the deal's long-term strategic significance.
See More
Theravance Biopharma Acquired by Zymeworks for $17 per Share
- Acquisition Agreement: Theravance Biopharma has entered into a definitive agreement with Zymeworks to be acquired for $17 per share in cash, representing an equity value of approximately $929 million, reflecting market recognition of Theravance's assets.
- Shareholder Benefit Assurance: In addition to cash, Theravance shareholders will receive a contingent value right entitling them to 80% of net proceeds from any future licensing or monetization of ampreloxetine over the next ten years, ensuring their interests in potential future gains.
- Strategic Review Outcome: This transaction is the result of a comprehensive evaluation by Theravance's Strategic Review Committee aimed at maximizing shareholder value, which previously included monetizing the TRELEGY® royalty for $225 million.
- Future Outlook: The transaction is expected to close in the second half of 2026, subject to shareholder and regulatory approvals, providing immediate cash flow to Theravance shareholders while preserving opportunities for future potential earnings.
See More
Zymeworks Acquires Theravance Biopharma for $929 Million
- Acquisition Overview: Zymeworks is acquiring Theravance Biopharma for $17 per share, totaling approximately $929 million, with the transaction expected to close in the second half of 2026, significantly enhancing Zymeworks' product portfolio and revenue sources.
- Cash Flow Expectations: The acquisition of YUPELRI® is projected to generate around $60 million in annual cash flow for Zymeworks, alongside existing cash flows from Ziihera®, supporting ongoing investments in R&D and shareholder returns.
- Innovative Financing Structure: The acquisition is primarily financed through a $350 million non-recourse note, minimizing Zymeworks' capital risk while preserving financial flexibility, with an expected reduction of approximately 50% in net investment.
- Strategic Development Direction: Zymeworks plans to optimize its R&D and commercialization strategies by integrating Theravance Biopharma's assets, further driving long-term shareholder value creation, particularly in response to the growing market demand for COPD treatments.
See More
Theravance Biopharma Under Investigation for Securities Fraud Claims
- Securities Fraud Investigation: Pomerantz LLP is investigating claims against Theravance Biopharma, Inc. regarding potential securities fraud and unlawful business practices by the company and its executives, which could lead to significant investor losses.
- Clinical Trial Failure: On March 3, 2026, Theravance announced that its Phase 3 CYPRESS study for ampreloxetine, aimed at treating neurogenic orthostatic hypotension, failed to meet its primary endpoint, prompting the company to wind down the program and negatively impacting investor confidence.
- Significant Stock Drop: Following the disappointing clinical trial results, Theravance's stock price plummeted by $4.99, or 26.33%, closing at $13.96 per share on March 3, 2026, indicating market concerns regarding the company's future prospects.
- Legal Firm Involvement: Pomerantz LLP, a prominent firm in securities class action litigation, has been advocating for investor rights for over 85 years and is currently offering legal support to affected investors, which may lead to further legal actions.
See More
Theravance Biopharma Q1 Earnings Analysis
- Earnings Report: Theravance Biopharma reported a Q1 GAAP EPS of -$0.10, missing expectations by $0.13, indicating challenges in profitability that could impact investor confidence.
- Revenue Growth: The company achieved Q1 revenue of $17.7 million, a 14.9% year-over-year increase, beating market expectations by $0.25 million, suggesting sustained demand for its products and laying a foundation for future business expansion.
- Drug Development Setback: Theravance dropped a rare disease drug after a late-stage trial failure, reflecting significant risks in its R&D pipeline that could negatively affect future revenue sources.
- Investment Moves: Summers Value Fund increased its stake in TBPH while exiting ADMA in Q1, indicating growing confidence in Theravance, which may attract other investors looking at its potential 50-100% upside.
See More
Theravance Biopharma to be Acquired by Zymeworks for $17.00 per Share
- Acquisition Details: Theravance Biopharma has entered into a definitive agreement with Zymeworks to be acquired for $17.00 per share in cash, representing an equity value of approximately $929 million, highlighting recognition of the company's assets and future potential.
- Shareholder Benefit Assurance: In addition to cash, Theravance shareholders will receive a contingent value right entitling them to 80% of net proceeds from any future monetization of ampreloxetine over the next ten years, enhancing the investment appeal by providing additional revenue opportunities.
- Strategic Review Process: This transaction follows a comprehensive evaluation by the company's Strategic Review Committee and Board of Directors, demonstrating the company's commitment to maximizing shareholder value, which previously included the successful monetization of a $225 million royalty interest in TRELEGY®.
- Future Outlook: The transaction is expected to close in the second half of 2026, subject to shareholder approval and customary closing conditions, and upon completion, it will provide immediate cash flow to Theravance shareholders while preserving future potential earnings from ampreloxetine.
See More
Zymeworks Acquires Theravance Biopharma for $929M
- Acquisition Overview: Zymeworks announced its acquisition of Theravance Biopharma in an all-cash deal valued at approximately $929 million, paying $17 per share, aimed at expanding its commercial portfolio with the COPD treatment YUPELRI.
- Financial Impact Analysis: YUPELRI currently generates about $60 million in annual cash flow, and the acquisition includes additional royalty interests, milestone payments, and approximately $2.5 billion in Irish tax attributes, which are expected to significantly enhance Zymeworks' financial position.
- Financing Structure: The deal will be financed primarily through a $350 million non-recourse note from OMERS Life Sciences, Theravance's expected $360 million net cash balance at closing, and $219 million of Zymeworks' cash, showcasing a diverse financing strategy.
- Approval and Expectations: The boards of both companies have unanimously approved the transaction, which is expected to close in the second half of 2026; however, TBPH stock dropped 3% in pre-market trading on Monday, indicating some market skepticism despite the deal's long-term strategic significance.
See More
Theravance Biopharma Acquired by Zymeworks for $17 per Share
- Acquisition Agreement: Theravance Biopharma has entered into a definitive agreement with Zymeworks to be acquired for $17 per share in cash, representing an equity value of approximately $929 million, reflecting market recognition of Theravance's assets.
- Shareholder Benefit Assurance: In addition to cash, Theravance shareholders will receive a contingent value right entitling them to 80% of net proceeds from any future licensing or monetization of ampreloxetine over the next ten years, ensuring their interests in potential future gains.
- Strategic Review Outcome: This transaction is the result of a comprehensive evaluation by Theravance's Strategic Review Committee aimed at maximizing shareholder value, which previously included monetizing the TRELEGY® royalty for $225 million.
- Future Outlook: The transaction is expected to close in the second half of 2026, subject to shareholder and regulatory approvals, providing immediate cash flow to Theravance shareholders while preserving opportunities for future potential earnings.
See More
Zymeworks Acquires Theravance Biopharma for $929 Million
- Acquisition Overview: Zymeworks is acquiring Theravance Biopharma for $17 per share, totaling approximately $929 million, with the transaction expected to close in the second half of 2026, significantly enhancing Zymeworks' product portfolio and revenue sources.
- Cash Flow Expectations: The acquisition of YUPELRI® is projected to generate around $60 million in annual cash flow for Zymeworks, alongside existing cash flows from Ziihera®, supporting ongoing investments in R&D and shareholder returns.
- Innovative Financing Structure: The acquisition is primarily financed through a $350 million non-recourse note, minimizing Zymeworks' capital risk while preserving financial flexibility, with an expected reduction of approximately 50% in net investment.
- Strategic Development Direction: Zymeworks plans to optimize its R&D and commercialization strategies by integrating Theravance Biopharma's assets, further driving long-term shareholder value creation, particularly in response to the growing market demand for COPD treatments.
See More
Theravance Biopharma Under Investigation for Securities Fraud Claims
- Securities Fraud Investigation: Pomerantz LLP is investigating claims against Theravance Biopharma, Inc. regarding potential securities fraud and unlawful business practices by the company and its executives, which could lead to significant investor losses.
- Clinical Trial Failure: On March 3, 2026, Theravance announced that its Phase 3 CYPRESS study for ampreloxetine, aimed at treating neurogenic orthostatic hypotension, failed to meet its primary endpoint, prompting the company to wind down the program and negatively impacting investor confidence.
- Significant Stock Drop: Following the disappointing clinical trial results, Theravance's stock price plummeted by $4.99, or 26.33%, closing at $13.96 per share on March 3, 2026, indicating market concerns regarding the company's future prospects.
- Legal Firm Involvement: Pomerantz LLP, a prominent firm in securities class action litigation, has been advocating for investor rights for over 85 years and is currently offering legal support to affected investors, which may lead to further legal actions.
See More
Theravance Biopharma Q1 Earnings Analysis
- Earnings Report: Theravance Biopharma reported a Q1 GAAP EPS of -$0.10, missing expectations by $0.13, indicating challenges in profitability that could impact investor confidence.
- Revenue Growth: The company achieved Q1 revenue of $17.7 million, a 14.9% year-over-year increase, beating market expectations by $0.25 million, suggesting sustained demand for its products and laying a foundation for future business expansion.
- Drug Development Setback: Theravance dropped a rare disease drug after a late-stage trial failure, reflecting significant risks in its R&D pipeline that could negatively affect future revenue sources.
- Investment Moves: Summers Value Fund increased its stake in TBPH while exiting ADMA in Q1, indicating growing confidence in Theravance, which may attract other investors looking at its potential 50-100% upside.
See More
